论文部分内容阅读
目的观察坎地沙坦酯片预防持续性心房颤动(房颤)首次复律成功后复发的疗效。方法将78例持续性房颤首次复律成功后的患者随机均分为治疗组和对照组。对照组予原发病治疗并加用华法林片、胺碘酮片;治疗组在对照组基础上再加用坎地沙坦酯片4mg/d口服。两组均连续治疗6个月,观察两组疗效。结果治疗组和对照组分别有36例和34例完成全程治疗。治疗组治愈9例,显效13例,有效10例;对照组治愈4例,显效7例,有效12例;治疗组治疗的总有效率高于对照组(88.89%vs.67.65%)(P<0.05)。两组患者均未见明显药物不良反应。结论坎地沙坦酯片预防持续性房颤患者首次复律成功后复发的疗效良好。
Objective To observe the efficacy of candesartan cilexetil in preventing relapse after the first cardioversion of persistent atrial fibrillation (AF). Methods 78 patients with persistent atrial fibrillation after first cardioversion were randomly divided into treatment group and control group. The control group was treated with the primary disease and added warfarin tablets and amiodarone tablets; the treatment group was treated with candesartan cilexetil 4 mg / d on the basis of the control group. Two groups were continuous treatment for 6 months, the two groups were observed. Results The treatment group and the control group, 36 cases and 34 cases completed the whole treatment. In the treatment group, 9 cases were cured, 13 cases were markedly effective and 10 cases were effective. In the control group, 4 cases were cured, 7 cases were markedly effective and 12 cases were effective. The total effective rate of the treatment group was higher than that of the control group (88.89% vs.67.65%, P < 0.05). No obvious adverse drug reactions in both groups. Conclusion Candesartan Ethacrylate tablets are effective in preventing relapse after first cardioversion in patients with persistent AF.